Description
Profender Spot-On For Cats 5.5-11 lbs (2.5-5 kg) is a single-dose spot-on dewormer for cats addressing hookworm, roundworm, and tapeworm infections in a single application. The formulation contains 15 mg emodepside, a cyclic depsipeptide acting against nematodes, combined with 60 mg praziquantel, an isoquinoline cestocide targeting tapeworms.
Recommended for
Cats and kittens weighing 5.5–11 lbs (2.5–5 kg) from 8 weeks of age.
Indication/Coverage
For cats suffering from, or at risk from, mixed intestinal worm infections, Profender Spot-On For Cats 5.5–11 lbs addresses the following parasitic conditions:
- Hookworm treatment: Eliminates Ancylostoma tubaeforme adults, immature adults, and fourth-stage larvae (L4) via topical absorption and systemic distribution.
- Roundworm treatment: Clears Toxocara cati infections across adult, immature adult, and fourth-stage larval (L4) stages.
- Tapeworm treatment: Eradicates Dipylidium caninum adults and Taenia taeniaeformis adults through the cestocidal action of praziquantel.
Key Benefits
Profender Spot-On For Cats 5.5–11 lbs delivers the following clinically documented actions:
- Age-appropriate dosing: Formulated for cats from 8 weeks of age weighing a minimum of 2.5 kg, covering the full 5.5–11 lbs weight band with the medium-size pipette containing 0.70 mL solution.
- Dual active ingredients: Emodepside (a cyclic depsipeptide) and praziquantel (an isoquinoline cestocide) address both nematode and cestode infections within a single application, removing the need for separate product types.
- Topical administration: Delivered directly to the skin at the base of the neck, bypassing oral dosing entirely. Cats that resist tablets or oral suspensions can be treated without stress-inducing handling.
- Broad larval coverage: Emodepside acts against immature adults and L4 larvae of Toxocara cati and Ancylostoma tubaeforme, not only adult worms, reducing the risk of re-establishment from developing stages.
- Single-dose efficacy: One application is effective, and a second treatment is not ordinarily required. Re-treatment is appropriate only if re-infection occurs after 30 days.
- Systemic distribution from skin contact: Following topical application, emodepside is absorbed transdermally and distributed systemically, reaching gastrointestinal parasites without oral ingestion.
- Established safety profile in multi-drug households: Field study data confirms safety in cats concurrently receiving analgesics, anti-fungals, NSAIDs, anthelmintics, antimicrobials, flea and tick products, sedatives, anesthetics, cardiac medications, anxiolytics, hormonal treatments, steroids, and otic and ophthalmic preparations.
Caution
Hazards to Humans
Keep out of reach of children. Avoid skin, eye, and clothing contact. Wash hands thoroughly with soap and warm water after handling. Children should not contact the application site for 24 hours following dosing. If accidental ingestion or eye exposure occurs, flush with water and contact a poison control center or physician.
Hazards to Domestic Animals
For external (dermal) use only. Do not apply to cats under 8 weeks of age or weighing less than 2.2 lbs (1 kg). Cats used for breeding, during pregnancy, or in lactation should receive this product with veterinary guidance, as safety in these groups has not been established. Do not use in sick or debilitated animals without prior veterinary assessment. Oral ingestion or environmental exposure should be avoided. The safety profile in heartworm-positive cats has not been evaluated; consult a veterinarian before administering to such animals.
Possible Side Effects
Monitor your cat closely in the hours following application. The adverse reactions listed below were reported in field and post-approval settings; all field study reactions were self-limiting.
Dermal reactions: Licking/excessive grooming (3.0%), scratching at the application site (2.5%), and hair loss, dermatitis, pyoderma, edema, or erythema at the site have been observed.
Gastrointestinal signs: Salivation, lethargy, vomiting, and diarrhea have each been recorded at low frequency in field study data.
Systemic signs: Ataxia, hypersalivation, fever, hyperactivity, nervousness, mydriasis, twitching, and in rare post-approval cases, seizures and paresis have been reported to the FDA CVM. In isolated post-approval cases, death has been listed as an outcome. A complete listing of adverse reactions is maintained at fda.gov/reportanimalae.










Reviews
There are no reviews yet